|Awarded On||August 18, 2021|
|Title||Deciphering BRCA1-BARD1 E3 Ligase Activity in Genome Maintenance and Tumor Suppression|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Weixing Zhao|
|Cancer Sites||Breast, Ovary|
*Pending contract negotiation
Affected individuals with harmful genetic change (mutations) in BRCA1 have a greatly increased risk (10-40 times higher than people without mutations) of developing breast and ovarian cancers. Furthermore, the majority (approximately 70%) of breast cancers with BRCA1 mutations do not response to advanced cancer treatments (e.g., targeted drugs) and develop resistance to the traditional chemotherapy/radiotherapy quickly, thus display very aggressive tumor behavior with a poor prognosis. As such, there is an urgent need for learning more about cancers with BRCA1 mutations, particularly the triple negative breast cancers, and finding better treatments for these patients. BRCA1 has been well doc...